Citations

Clear

139 citation(s) found for "Anderson, Kenneth C".

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Richardson, Paul G. , Vij, Ravi , Chen, Christine , Jakubowiak, Andrzej , Song, Kevin , Belch, Andrew , Shustik, Chaim, Lentzsch, Suzanne , Lacy, Martha Q. , Matous, Jeffrey, Vesole, David H. , Chen, Min , Zaki, Mohamed H. , Jacques, Christian , Yu, Zhinuan, Richardson, Paul Gerard Guy , Siegel, David S. , Hofmeister, Craig C. , Baz, Rachid , Jagannath, Sundar , Lonial, Sagar , Bahlis, Nizar Jacques , Raje, Noopur , Mıkhael, Joseph , Anderson, Kenneth C.

Mayo Clinic

Blood | January 13, 2014 | Volume: 123 | Issue: 12 | Pages: 1826-1832

10.1182/blood-2013-11-538835 | PMID 24421329 Get It

Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.
Abstract B58: Decreasing the time to activate clinical trials: Initial data from the Multiple Myeloma Research Consortium (MMRC) model
Wear, Sandra, Kelley, Susan L., Quinn-Young, Anne, Kumar, Shaji , Jakubowiak, Andzej, Lonial, Sagar , Anderson, Kenneth C.

Mayo Clinic

Molecular Cancer Therapeutics | June 27, 2012 | Volume: 8 | Issue: 12_Supplement | Pages: B58-B58

10.1158/1535-7163.targ-09-b58 Get It

Abstract Background: Activation of oncology trials is a lengthy and complex process. Recent literature has identified numerous opportunities to improve activation timelines1, 2. The Multiple Myeloma Research Consortium (MMRC) has implemented several processes to identify and overcome myeloma clinical trial activation barriers within the consortium network of 14 North American cancer centers. We examined the impact of these processes preand post- implementation and also compared activation times with published clinical trial metrics data. Methods/Results: 12 MMRC-facilitated trials had sufficient trial data available for review within the study period of May 2006 to March 2009. Activation time was defined as the time from a center's receipt of the final clinical trial protocol from the sponsor, to the time the first patient was enrolled into a trial at any MMRC participating center. The earlier group (EG) of MMRC trials (n=7) required a mean of 257 calendar days for activation, comparable to the mean published data of 251 calendar days1. The more recent group (RG) of MMRC trials (n=5) required a mean of 158 calendar days for activation, representing a 38% shortening of activation time. Additionally, implementation of standardized processes and rigorous project management resulted in a reduction in activation times for all MMRC centers in a given trial from a mean of 7.5 months to a mean of 5.1 months. Improving the mean time of several several specific steps in the process including time to initial protocol review submission from receipt (EG=37 vs. RG=19 days), scientific review committee time (EG=98 vs. RG=55 days), and the time from trial opening to first patient dosed (EG=74 vs. RG=27 days) contributed to the overall decrease in activation times. The EG metrics data are comparable to published data1 for each process step. Conclusion: The MMRC member institutions have seen substantial improvements in trial activation times and are in the process of implementing additional processes to further improve protocol development and trial conduct metrics. The efficiencies and process improvements realized from application of rigorous MMRC project management resources and the standardization of contracting and other key activities may be applied in other areas of oncology clinical trials beyond multiple myeloma. With increasing numbers of new oncology agents to be evaluated and greater pressure on trial sponsors to introduce efficiencies into trial timelines, overcoming such barriers is of critical importance. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B58.
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
Cavo, Michèle , Rajkumar, S. Vincent , Palumbo, Antonio , Moreau, Philippe , Orlowski, Robert Z. , Bladé, Joan , Sezer, Orhan , Dimopoulos, Meletios Α. , Sonneveld, Pieter , Boccadoro, Mario , Richardson, Paul G. , Bensinger, William, Johnsen, Hans Erik , Gahrton, Gösta , Bergsagel, P. Leif , Vesole, David H., Niesvizky, Rubén, Durie, Brian G.M. , Miguel, Jesús F. San , Bergsagel, P. Leif , Orlowski, Robert Z. , Ludwig, Heinz , Attal, Michel , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Kröger, Nicolaus , Einsele, Hermann , Jagannath, Sundar , Lonial, Sagar , Rajkumar, S Vincent , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus

Mayo Clinic

Blood | March 30, 2011 | Volume: 117 | Issue: 23 | Pages: 6063-6073

10.1182/blood-2011-02-297325 | PMID 21447828 Get It

AbstractThe role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with traditional therapies and with one another to form various doublet, triplet, and quadruplet regimens. Up-front use of these induction treatments, in particular 3-drug combinations, has affected unprecedented rates of complete response that rival those previously seen with conventional chemotherapy and subsequent ASCT. Autotransplantation applied after novel-agent-based induction regimens provides further improvement in the depth of response, a gain that translates into extended progression-free survival and, potentially, overall survival. High activity shown by immunomodulatory derivatives and bortezomib before ASCT has recently led to their use as consolidation and maintenance therapies after autotransplantation. Novel agents and ASCT are complementary treatment strategies for MM. This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients.
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
Munshi, Nikhil C. , Bergsagel, P. Leif , Shaughnessy, John D. , Palumbo, Antonio , Durie, Brian G.M. , Fonseca, Rafaël , Stewart, A. Keith, Harousseau, Jean‐Luc, Dimopoulos, Meletios Α. , Hájek, Roman , Sezer, Orhan , Kyle, Robert A. , Sonneveld, Pieter , Cavo, Michèle , Rajkumar, S. Vincent , Miguel, Jesús F. San , Crowley, John, Avet‐Loiseau, Hervé , 2, on behalf of the International Myeloma Workshop Consensus Panel, Bergsagel, P. Leif , García‐Sánz, Ramón , Moreau, Philippe , Anderson, Kenneth C. , Stewart, A. Keith, Jagannath, Sundar , 2, on behalf of the International Myeloma Workshop Consensus Panel, Hajek, Roman , Rajkumar, S Vincent , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Garcia-Sanz, Ramon , Fonseca, Rafael

Mayo Clinic

Blood | February 4, 2011 | Volume: 117 | Issue: 18 | Pages: 4696-4700

10.1182/blood-2010-10-300970 | PMID 21292777 Get It

AbstractA panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk stratification is not to decide time of therapy but to prognosticate. There is general consensus that risk stratification is applicable to newly diagnosed patients; however, some genetic abnormalities characteristic of poor outcome at diagnosis may suggest poor outcome if only detected at the time of relapse. Thus, in good-risk patients, it is necessary to evaluate for high-risk features at relapse. Although detection of any cytogenetic abnormality is considered to suggest higher-risk disease, the specific abnormalities considered as poor risk are cytogenetically detected chromosomal 13 or 13q deletion, t(4;14) and del17p, and detection by fluorescence in situ hybridization of t(4;14), t(14;16), and del17p. Detection of 13q deletion by fluorescence in situ hybridization only, in absence of other abnormalities, is not considered a high-risk feature. High serum β2-microglobulin level and International Staging System stages II and III, incorporating high β2-microglobulin and low albumin, are considered to predict higher risk disease. There was a consensus that the high-risk features will change in the future, with introduction of other new agents or possibly new combinations.
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Dimopoulos, Meletios Α. , Kyle, Robert A. , Fermand, Jean-Paul, Rajkumar, S. Vincent , Miguel, Jesús F. San , Chanan‐Khan, Asher , Joshua, Douglas, Mehta, Jayesh, Avet‐Loiseau, Hervé , Beksaç, Meral , Moreau, Philippe , Goldschmidt, Hartmut , Boccadoro, Mario , Kumar, Shaji , Munshi, Nikhil C. , 3, on behalf of the International Myeloma Workshop Consensus Panel, Ludwig, Heinz , Gertz, Morie A. , Anderson, Kenneth C. , Singhal, Seema , Giralt, Sergio , Jagannath, Sundar , 3, on behalf of the International Myeloma Workshop Consensus Panel, Rajkumar, S Vincent , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Beksac, Meral

Mayo Clinic

Blood | February 4, 2011 | Volume: 117 | Issue: 18 | Pages: 4701-4705

10.1182/blood-2010-10-299529 | PMID 21292778 Get It

AbstractA panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monoclonal protein both by densitometer tracing and/by nephelometric quantitation is recommended, and immunofixation is required for confirmation. The serum-free light chain assay is recommended in all newly diagnosed patients with plasma cell dyscrasias. Bone marrow aspiration and/or biopsy along with demonstration of clonality of plasma cells are necessary. Serum β2-microglobulin, albumin, and lactate dehydrogenase are necessary for prognostic purposes. Standard metaphase cytogenetics and fluorescent in situ hybridization for 17p, t(4;14), and t(14;16) are recommended. The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse.
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
Rajkumar, S. Vincent , Harousseau, Jean‐Luc, Durie, Brian G.M. , Dimopoulos, Meletios Α. , Kyle, Robert A. , Bladé, Joan , Richardson, Paul G. , Orlowski, Robert Z. , Avet‐Loiseau, Hervé , Palumbo, Antonio , Zonder, Jeffrey A. , Vesole, David H., Sezer, Orhan , Munshi, Nikhil C. , Miguel, Jesús F. San , 1, on behalf of the International Myeloma Workshop Consensus Panel, Cavo, Michèle , García‐Sánz, Ramón , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Orlowski, Robert Z. , Siegel, David S. , Jagannath, Sundar , Facon, Thierry T.F. , Lonial, Sagar , Ludwig, Heinz , 1, on behalf of the International Myeloma Workshop Consensus Panel, Rajkumar, S Vincent , Dimopoulos, Meletios A , San-Miguel, Jesus , Garcia-Sanz, Ramon

Mayo Clinic

Blood | February 4, 2011 | Volume: 117 | Issue: 18 | Pages: 4691-4695

10.1182/blood-2010-10-299487 | PMID 21292775 Get It

Abstract It is essential that there be consistency in the conduct, analysis, and reporting of clinical trial results in myeloma. The goal of the International Myeloma Workshop Consensus Panel 1 was to develop a set of guidelines for the uniform reporting of clinical trial results in myeloma. This paper provides a summary of the current response criteria in myeloma, detailed definitions for patient populations, lines of therapy, and specific endpoints. We propose that future clinical trials in myeloma follow the guidelines for reporting results proposed in this manuscript.
Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
Dimopoulos, Meletios Α. , Terpos, Evangelos , Chanan-Khan, Asher, Leung, Nelson , Niesvizky, Rubén, Fermand, Jean-Paul, Bladé, Joan , Comenzo, Raymond L. , Sezer, Orhan , Palumbo, Antonio , Harousseau, Jean‐Luc, Richardson, Paul G. , Barlogie, Bart , Sonneveld, Pieter , Tosi, Patrizia , Cavo, Michèle , Rajkumar, S. Vincent , Durie, Brian G.M. , Miguel, Jesús F. San , Ludwig, Heinz , Jagannath, Sundar , Giralt, Sergio , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Rajkumar, S Vincent , Leung, Nelson , Dimopoulos, Meletios A , Terpos, Evangelos , San-Miguel, Jesus

Mayo Clinic

Journal of Clinical Oncology | October 19, 2010 | Volume: 28 | Issue: 33 | Pages: 4976-4984

10.1200/jco.2010.30.8791 | PMID 20956629 Get It

Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is the recommended method for the assessment of renal function in patients with MM with stabilized serum creatinine. In acute renal injury, the RIFLE (risk, injury, failure, loss and end-stage kidney disease) and Acute Renal Injury Network criteria seem to be appropriate to define the severity of renal impairment. Novel criteria based on eGFR measurements are recommended for the definition of the reversibility of renal impairment. Rapid intervention to reverse renal dysfunction is critical for the management of these patients, especially for those with light chain cast nephropathy. Bortezomib with high-dose dexamethasone is considered as the treatment of choice for such patients. There is limited experience with thalidomide in patients with myeloma with renal impairment. Thus, thalidomide can be carefully administered, mainly in the context of well-designed clinical trials, to evaluate if it can improve the rapidity and probability of response that is produced by the combination with bortezomib and high-dose dexamethasone. Lenalidomide is effective in this setting and can reverse renal insufficiency in a significant subset of patients, when it is given at reduced doses, according to renal function. The role of plasma exchange in patients with suspected light chain cast nephropathy and renal impairment is controversial. High-dose melphalan (140 mg/m2) and autologous stem-cell transplantation should be limited to younger patients with chemosensitive disease.
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia
LaPlant, Betsy, Camoriano, John , Hayman, Suzanne R. , Lacy, Martha Q. , Chuma, Stacey, Harris, Brianna , Leduc, Renee, Rourke, Meghan, Ansell, Stephen M. , Dispenzieri, Angela , Bergsagel, Leif, Reeder, Craig B. , Richardson, Paul G. , Bergsagel, P. Leif , Borchin, Renée , Ghobrial, Irene M. , Gertz, Morie A. , DeAngelo, Daniel J. , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Treon, Steven P. , Witzig, Thomas E. , Bergsagel, P. Leif , Dispenzieri, Angela , Harris, Brianna N

Mayo Clinic

Journal of Clinical Oncology | February 8, 2010 | Volume: 28 | Issue: 8 | Pages: 1408-1414

10.1200/jco.2009.24.0994 | PMID 20142598 Get It

Purpose The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell proliferation and survival. Everolimus is an oral agent targeting raptor mTOR (mTORC1). The trial's goal was to determine the antitumor activity and safety of single-agent everolimus in patients with relapsed/refractory Waldenström macroglobulinemia (WM). Patients and Methods Eligible patients had measurable disease (immunoglobulin M monoclonal protein > 1,000 mg/dL with > 10% marrow involvement or nodal masses > 2 cm), a platelet count more than 75,000 × 10 6 /L, a neutrophil count more than 1,000 × 10 6 /L, and a creatinine and bilirubin less than 2 × the laboratory upper limit of normal. Patients received everolimus 10 mg orally daily and were evaluated monthly. Tumor response was assessed after cycles 2 and 6 and then every three cycles until progression. Results Fifty patients were treated. The median age was 63 years (range, 43 to 85 years). The overall response rate (complete response plus partial remission [PR] plus minimal response [MR]) was 70% (95% CI, 55% to 82%), with a PR of 42% and 28% MR. The median duration of response and median progression-free survival (PFS) have not been reached. The estimated PFS at 6 and 12 months is 75% (95% CI, 64% to 89%) and 62% (95% CI, 48% to 80%), respectively. Grade 3 or higher related toxicities were observed in 56% of patients. The most common were hematologic toxicities with cytopenias. Pulmonary toxicity occurred in 10% of patients. Dose reductions due to toxicity occurred in 52% of patients. Conclusion Everolimus has high single-agent activity with an overall response rate of 70% and manageable toxicity in patients with relapsed WM and offers a potential new therapeutic strategy for this patient group.
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome
Driscoll, James J. , Pelluru, Dheeraj, Lefkimmiatis, Konstantinos , Fulciniti, Mariateresa , Prabhala, Rao , Greipp, Philip R., Barlogie, Bart , Shaughnessy, John D. , Munshi, Nikhil C. , Tai, Yu‐Tzu , Anderson, Kenneth C. , Annunziata, Christina M.

Mayo Clinic

Blood | November 30, 2009 | Volume: 115 | Issue: 14 | Pages: 2827-2834

10.1182/blood-2009-03-211045 | PMID 19965618 Get It

Abstract Multiple myeloma (MM) is a plasma cell neoplasm that proceeds through a premalignant state of monoclonal gammopathy of unknown significance; however, the molecular events responsible for myelomagenesis remain uncharacterized. To identify cellular pathways deregulated in MM, we addressed that sumoylation is homologous to ubiquitination and results in the attachment of the ubiquitin-like protein Sumo onto target proteins. Sumoylation was markedly enhanced in MM patient lysates compared with normal plasma cells and expression profiling indicated a relative induction of sumoylation pathway genes. The Sumo-conjugating enzyme Ube2I, the Sumo-ligase PIAS1, and the Sumo-inducer ARF were elevated in MM patient samples and cell lines. Survival correlated with expression because 80% of patients with low UBE2I and PIAS1 were living 6 years after transplantation, whereas only 45% of patients with high expression survived 6 years. UBE2I encodes the sole Sumo-conjugating enzyme in mammalian cells and cells transfected with a dominant-negative sumoylation-deficient UBE2I mutant exhibited decreased survival after radiation exposure, impaired adhesion to bone marrow stroma cell and decreased bone marrow stroma cell–induced proliferation. UBE2I confers cells with multiple advantages to promote tumorigenesis and predicts decreased survival when combined with PIAS1. The sumoylation pathway is a novel therapeutic target with implications for existing proteasomal-based treatment strategies.
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Kumar, Shaji , Stadtmauer, Edward A. , Harousseau, Jean Luc, Palumbo, Antonio, Bensinger, William, Comenzo, Raymond L. , Lentzsch, Suzanne , Munshi, Nikhil C. , Niesvizky, Rubén, Miguel, Jesús F. San , Bergsagel, Leif, Bladé, Joan , Tosi, Patrizia , Sonneveld, Pieter , Sezer, Orhan , Vesole, David H., Cavo, Michèle , Richardson, Paul G. , Durie, Brian G.M. , Rajkumar, S. Vincent , Bergsagel, P. Leif , Giralt, Sergio , Ludwig, Heinz , Lonial, Sagar , Anderson, Kenneth C. , Einsele, Hermann , Richardson, Paul Gerard Guy , Bergsagel, P. Leif , Rajkumar, S Vincent , San-Miguel, Jesus

Mayo Clinic

Blood | June 27, 2009 | Volume: 114 | Issue: 9 | Pages: 1729-1735

10.1182/blood-2009-04-205013 | PMID 19561323 Get It

The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization.